| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(8 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(10 years from now) | |
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(12 years from now) | |
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
| US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(8 years from now) | |
Lokelma is owned by Astrazeneca.
Lokelma contains Sodium Zirconium Cyclosilicate.
Lokelma has a total of 13 drug patents out of which 0 drug patents have expired.
Lokelma was authorised for market use on 18 May, 2018.
Lokelma is available in for suspension;oral dosage forms.
Lokelma can be used as treatment of hyperkalemia in adults.
Drug patent challenges can be filed against Lokelma from 2022-05-18.
The generics of Lokelma are possible to be released after 14 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 18, 2023 |
| M (M) | Apr 24, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 2022-05-18
Market Authorisation Date: 18 May, 2018
Treatment: Treatment of hyperkalemia in adults
Dosage: FOR SUSPENSION;ORAL
LOKELMA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic